Elutax Real World

03.10.2009
 
 


To
whom
it
may
concern
 
 Since
July
2008
Elutax
drug
eluting
balloons
(ELUTAX®
2nd
generation,
produced
by
 AACHEN
RESONANCE)
are
available
in
the
Heart
Center
of
University
Giessen
and
 Marburg,
as
well
at
Campus
Giessen
as
at
Campus
Marburg.
 Main
indication
for
the
use
of
DEB
was
the
treatment
of
BMS
in‐stent
restenoses.
 Another
indication
was
the
treatment
of
stenoses
in
small
peripheral
vessels
(<
2
mm).
 There
were
few
patients
with
diabetes
mellitus
and
indication
for
DES‐implantation
 parallel
to
an
indication
for
abdominal
surgery.
In
these
patients
target
lesion
was
 dilated
using
Elutax
DEB
prior
to
BMS
implantation.
 Handling
and
preparation
of
the
Elutax
system
were
without
any
problems.
Steerability
 and
deliverability
of
the
Elutax
system
are
good,
except
in
very
tortuous
vessels.
In
very
 stenoses,
pre‐dilatation
has
to
be
recommended.
 For
the
passage
into
side
branches
through
stent
struts,
pre‐dilatation
with
low‐profile
 uncoated
balloons
is
necessary.
 Acute
results
of
Elutax
application
in
more
than
70
cases
were
satisfying
without
 exception
during
the
last
months.
Due
to
routinely
performed
angiographic
controls
six
 months
after
intervention,
excellent
long
term
results
could
be
proven.
There
are
no
 signs
of
elevated
late
loss
rates.
 In
conclusion,
Elutax
drug
eluting
balloons
can
be
strongly
recommended
for
therapy
of
 BMS
in‐stent
stenoses
as
well
as
of
stenoses
in
small
peripheral
coronary
vessels.
 
 Priv.
Doz.
Dr.
Martin
C.
Heidt
 Arzt
für
Innere
Medizin,
 Kardiologie,
Angiologie,
 Internistische
Intensivmedizin,
 Notfallmedizin,
 Hypertensiologie
DHL
 Leitender
Oberarzt
des
Herzkatheterlabors
 Abt.
Kardiologie/
Angiologie
 Zentrum
für
Innere
Medizin
 Universitätsklinikum
Gießen
und
Marburg
 Standort
Marburg
 Baldingerstrasse
1
 35043
Marburg